BYSANTI (milsaperidone), a new atypical antipsychotic from Vanda Pharmaceuticals, gains FDA approval for acute manic or mixed episodes in bipolar I disorder and schizophrenia in adults, with US launch planned for Q3 2026.
FDA Approval | 21/02/2026 | By News Bureau | 216
Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria
Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.
FDA Approval | 19/02/2026 | By News Bureau | 120
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
FDA Approval | 19/01/2026 | By News Bureau | 406
BD Secures FDA 510(k) Clearance for EnCor EnCompass Multi-Modality Breast Biopsy System
BD has received FDA 510(k) clearance for its EnCor EnCompass multi-modality breast biopsy system, designed to improve procedural efficiency, clinician flexibility and early detection and diagnosis of breast disease.
FDA Approval | 17/01/2026 | By News Bureau | 141
The silicon photonics based imaging platform, Leadoptik’s LIA system, delivers real-time, high-resolution tissue insight at the point of care, addressing a critical gap in lung cancer diagnosis.
FDA Approval | 16/01/2026 | By News Bureau | 308
Esaote, a global leader in medical device manufacturing specializing in ultrasound, dedicated MRI, and healthcare IT, announced that its MyLab A50 and MyLab A70 ultrasound systems have received FDA approval.
FDA Approval | 25/08/2025 | By Darshana | 223
EBR Systems Secures FDA Approval for WiSE System to Treat Advanced Heart Failure
Unlike conventional CRT, the WiSE System is the first and only to deliver leadless left ventricular endocardial pacing (LVEP), that closely aligns with the heart's natural conduction pathway.
FDA Approval | 19/04/2025 | By Abha | 464
Fapon Biopharma Receives FDA Approval of IND for FP008 for Solid Tumors
FP008 is a novel anti-PD-1×IL-10M fusion protein with a unique mechanism of action (MOA) and therapeutic potential for anti-PD-1 naïve or resistant patients.
FDA Approval | 03/03/2025 | By Aishwarya | 353
Nexus Pharmaceuticals Secures FDA Approval for Tacrolimus Injection
Tacrolimus Injection 5 mg/mL (Single-Dose Vial) in a 10-pack will be launching soon.
FDA Approval | 15/02/2025 | By Aishwarya | 435
American Injectables Secures FDA Approval
American Injectables, specialising in sterile injectables, has announced that it has received FDA approval.
FDA Approval | 10/01/2025 | By Abha | 427
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy